Mandate

Vinge advises EQT IX in connection with the acquisition of Parexel

December 14, 2021 EU, Competition and Regulatory

Vinge has advised EQT IX on the merger control aspects of EQT IX’s and Goldman Sachs Asset Management’s acquisition of Parexel from Pamplona Capital Management for USD 8.5 billion.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. The acquisition was notified to a number of competition authorities worldwide including to the European Commission. Vinge’s team consisted primarily of Emma Johansson, Johan Wahlbom, Victoria Fredén and Jesper Ekman.

Related

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026

Vinge has advised Morrow Bank in connection with its issuances of primary capital instruments (AT1) and tier 2 capital bonds (T2)

The issuances comprised perpetual AT1 bonds of NOK 300 million with a floating coupon of 3-month NIBOR + 425 basis points and a first call date in 2031, as well as subordinated Tier 2 bonds of SEK 200 million with a floating coupon of 3-month STIBOR + 325 basis points and a first call date in 2031. The bonds are intended to be admitted to trading on Nasdaq Stockholm.
July 03, 2026

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026